Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 10Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Brain Neoplasms 3Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Mouth Neoplasms 2Medulloblastoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphatic System Neoplasm 2Glioblastoma 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2

Interventions

Everolimus 6lutetium Lu 177 dotatate 5lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2fluorodopa F 18 2Introns 2telotristat ethyl 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Temozolomide 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Leucovorin 1Interferon alpha-2 1Immunoglobulin G 1Ga(III)-DOTATOC 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neuroendocrine Tumors × Specimen Handling × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡